Developers and brokers are using multiple strategies to bring life sciences companies out past Route 128 in Massachusetts. They cite less expensive real estate, a strong talent pool, shorter commutes, and increasing amenities like culture, sports, and food as reasons to set up shop in Central Massachusetts.
Figures for the first quarter of 2022: Sales revenue up 25.4 percent in constant currencies, underlying EBITDA up 32.4 percent, underlying EBITDA margin 34.1.